In the current meta-analysis of clinical trials, we demonstrated that the median OS, PFS, ORR, DCR, 1 year survival rate, and 2 year survival rate for ALK inhibitors including crizotinib, ceritinib, and alectinib in the treatment of ALK-positive NSCLC was 19.14 months, 8.47 months, 62%, 78%, 74%, and 62%, respectively. This evidence concerns the gene ALK and non-small cell lung carcinoma.